Trackability of proteins from probiotic Bifidobacterium spp. in the gut using metaproteomics
Issued Date
2023-01-01
Resource Type
ISSN
18762883
eISSN
18762891
Scopus ID
2-s2.0-85191384129
Pubmed ID
38661361
Journal Title
Beneficial Microbes
Volume
14
Issue
3
Start Page
269
End Page
280
Rights Holder(s)
SCOPUS
Bibliographic Citation
Beneficial Microbes Vol.14 No.3 (2023) , 269-280
Suggested Citation
Hendrickx D.M., An R., Boeren S., Mutte S.K., Wopereis H., Belzer C., Chatchatee P., Nowak Wegrzyn A., Lange L., Benjaponpitak S., Wee Chong K., Sangsupawanich P., Van Ampting M.T.J., Oude Nijhuis M.M., Harthoorn L.F., Langford J.E., Knol J., Knipping K., Garssen J., Trendelenburg V., Pesek R., Davis C.M., Muraro A., Erlewyn-Lajeunesse M., Fox A.T., Michaelis L.J., Beyer K., Noimark L., Stiefel G., Schauer U., Hamelmann E., Peroni D., Boner A. Trackability of proteins from probiotic Bifidobacterium spp. in the gut using metaproteomics. Beneficial Microbes Vol.14 No.3 (2023) , 269-280. 280. doi:10.1163/18762891-20220137 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/101313
Title
Trackability of proteins from probiotic Bifidobacterium spp. in the gut using metaproteomics
Author(s)
Hendrickx D.M.
An R.
Boeren S.
Mutte S.K.
Wopereis H.
Belzer C.
Chatchatee P.
Nowak Wegrzyn A.
Lange L.
Benjaponpitak S.
Wee Chong K.
Sangsupawanich P.
Van Ampting M.T.J.
Oude Nijhuis M.M.
Harthoorn L.F.
Langford J.E.
Knol J.
Knipping K.
Garssen J.
Trendelenburg V.
Pesek R.
Davis C.M.
Muraro A.
Erlewyn-Lajeunesse M.
Fox A.T.
Michaelis L.J.
Beyer K.
Noimark L.
Stiefel G.
Schauer U.
Hamelmann E.
Peroni D.
Boner A.
An R.
Boeren S.
Mutte S.K.
Wopereis H.
Belzer C.
Chatchatee P.
Nowak Wegrzyn A.
Lange L.
Benjaponpitak S.
Wee Chong K.
Sangsupawanich P.
Van Ampting M.T.J.
Oude Nijhuis M.M.
Harthoorn L.F.
Langford J.E.
Knol J.
Knipping K.
Garssen J.
Trendelenburg V.
Pesek R.
Davis C.M.
Muraro A.
Erlewyn-Lajeunesse M.
Fox A.T.
Michaelis L.J.
Beyer K.
Noimark L.
Stiefel G.
Schauer U.
Hamelmann E.
Peroni D.
Boner A.
Author's Affiliation
Great North Children's Hospital
Nutricia Research, Netherlands
Utrechts Instituut voor Farmaceutische Wetenschappen
Azienda Ospedaliera Universitaria Integrata Verona
NYU Langone Health
St. Marien Hospital, Bonn
Azienda Ospedale Università Padova
Charité – Universitätsmedizin Berlin
Faculty of Medicine, Prince of Songkla University
Uniwersytet Warminsko-Mazurski w Olsztynie
Faculty of Medicine Ramathibodi Hospital, Mahidol University
KK Women's And Children's Hospital
The Royal London Hospital
Leicester Royal Infirmary
Guy's and St Thomas' NHS Foundation Trust
Ruhr-Universitat Bochum
Wageningen University & Research
Arkansas Children's Hospital
Faculty of Medicine, Chulalongkorn University
Baylor College of Medicine
University Hospital Southampton NHS Foundation Trust
Nutricia Research, Netherlands
Utrechts Instituut voor Farmaceutische Wetenschappen
Azienda Ospedaliera Universitaria Integrata Verona
NYU Langone Health
St. Marien Hospital, Bonn
Azienda Ospedale Università Padova
Charité – Universitätsmedizin Berlin
Faculty of Medicine, Prince of Songkla University
Uniwersytet Warminsko-Mazurski w Olsztynie
Faculty of Medicine Ramathibodi Hospital, Mahidol University
KK Women's And Children's Hospital
The Royal London Hospital
Leicester Royal Infirmary
Guy's and St Thomas' NHS Foundation Trust
Ruhr-Universitat Bochum
Wageningen University & Research
Arkansas Children's Hospital
Faculty of Medicine, Chulalongkorn University
Baylor College of Medicine
University Hospital Southampton NHS Foundation Trust
Corresponding Author(s)
Other Contributor(s)
Abstract
Beneficial effects of Bifidobacterium spp. on gut microbiota development and infant health have been reported earlier. Therefore, supplementation of infant formulas with probiotic bifidobacteria, as well as prebiotics stimulating bifidobacterial growth, has been proposed. Here, we studied the faecal microbiome of infants supplemented with specialized nutrition, of which some received a standard amino acid-based formula (AAF) and others an AAF with a specific mixture of prebiotics and a probiotic (synbiotics) using metaproteomics and 16S rRNA gene sequencing. Faecal samples were taken at baseline, as well as after 6 and 12 months fed with the specialized formula. The aim was to compare microbial differences between infants treated with the standard AAF and those who received the additional synbiotics. Our findings show that infants who received AAF with synbiotics have significantly higher levels of Bifidobacteriaceae DNA as well as significantly increased levels of Coriobacteriaceae proteins, over time. Moreover, at visit 12 months higher levels of some bifidobacterial carbohydrate-active enzymes, known to metabolize oligosaccharides, were observed in the synbiotic group compared to the non-synbiotic group. The results indicate that the synbiotics provided in our study are trackable in faecal samples on the DNA and protein level during the intervention period.